NXL earnings analysis
What we found in NXL's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided 10-Q excerpt does not include current-period income statement, balance-sheet, segment, or cash-flow figures, so no reported Q2 2026 revenue, margin, EPS, or free-cash-flow trend can be quantified from the supplied text. The filing adds significant financing and listing pressure: Nasdaq delisting proceedings are pending after failure to meet the $1.00 bid-price requirement, and delisting could eliminate ATM access. Two material internal-control weaknesses remain, while the PONM acquisition introduces execution, related-party, and dilution risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- PONM acquisition completed
- The Company completed the PONM, Inc. acquisition on May 14, 2026 for aggregate consideration of approximately $1.3 million, including an exclusive licensed technology asset recorded at approximately $700,000.
- Reverse-split plan approved
- The Board approved a 30-to-1 reverse stock split ratio after stockholders authorized reverse splits ranging from 1-for-2 to 1-for-100, subject to an aggregate maximum of 1-for-250.
- PONM consideration issued
- The Company issued 959,016 common shares with an initial fair value of approximately $725,000 as the first tranche of PONM acquisition consideration.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Pending Nasdaq delisting proceeding
- Nasdaq determined on July 24, 2026 that the Company had not regained compliance with the $1.00 minimum closing bid-price requirement after the initial 180-calendar-day compliance period expired on July 20, 2026. The Company requested a hearing, but continued listing is not assured and delisting could materially reduce liquidity and financing access.
- Potential loss of ATM financing
- If delisted, the Company expects to lose access to its ATM program because Form S-3 eligibility depends on continued national-exchange listing. The Company also states there is substantial doubt about its ability to continue as a going concern, potentially delaying or eliminating planned activities including its pivotal insomnia clinical trial.
- Material internal-control weaknesses
- The 10-Q identifies 2 material weaknesses in internal controls: insufficient segregation of duties and inadequate IT access controls. Management says remediation depends on hiring qualified personnel subject to budget limitations, and that redesign and implementation may be costly and time consuming.
- PONM execution and dilution risk
- The PONM technology requires additional development and customization, while the collaboration agreement with GLV has an initial term of only 24 months. Approximately $387,000 of acquisition consideration remained unpaid at June 30, 2026, and the number of future shares may increase substantially if the stock price declines or a reverse split occurs.
What they said about what is next.
No quantitative revenue or EPS outlook was disclosed in the provided 10-Q text; numeric guidance may be deferred to the earnings release or call.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 8, 2026
- Nexalin Technology, Inc. experienced significant revenue growth in Q4 2026, with reported revenue of $171,895, compared to $41,015 in the same quarter last year, marking a 319% increase. However, the company continued…
- 10-K · March 25, 2026
- Nexalin positions itself as a bioelectronic medical-device company focused on next-generation (Gen-2 SYNC, Gen-3 HALO) neurostimulation headsets and a virtual clinic model; management highlights FDA Q-Submission…
- 10-Q · May 13, 2025
- Nexalin reported Q1 2025 revenue of $41,015 (beat consensus $35,000 by ~17%) and improved revenue sequentially from $27,179 in Q4 2024 (+50.9%). Gross margin contracted to 66.9% from 72.4% in Q4 2024 and net loss…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NXL makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever